Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease: the RESET cohort study and randomized trial

Collaborative Grant funded programme that brings together a nationwide community of cardiovascular (CVD), metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early CV disease.RESET incorporates a nested randomized controlled trial (RCT) to test the use of a combined digital wearable and artificial intelligence (AI)-human symbiotic lifestyle intervention to halt or reverse the progression of early disease (Figure 1).